PURPOSE: Serum levels of amylase and lipase are frequently increased in patients with chronic kidney disease (CKD). Relatively low serum pancreatic enzyme levels in CKD may represent a state of pancreatic insufficiency and may contribute to protein-energy wasting (PEW). We aimed to investigate the relationships of serum pancreatic enzyme levels with PEW, inflammation, and mortality in CKD patients. METHODS: Two hundred and thirty CKD patients (male/female: 144/86; mean age, 59 ± 16 years) were enrolled. Serum total α-amylase and lipase activities were measured by enzymatic colorimetric assays. Mean follow-up time was 18 ± 10 months. Forty-seven patients (20 %) died during this period. RESULTS: Serum amylase levels were increased in 95 patients (41 %) and serum lipase levels were increased in 71 patients (30 %) out of the 230 patients. Diabetic patients had significantly lower serum amylase levels than non-diabetic ones (86 ± 46 vs. 111 ± 60 IU/L, p < 0.0001). Patients with ischemic heart disease also had significantly lower serum amylase (82 ± 37 vs. 108 ± 60 IU/L, p < 0.0001) and lipase levels (39 ± 36 vs. 57 ± 57 IU/L, p = 0.007). Serum amylase and lipase levels were directly correlated with serum creatinine (r = 0.173, p = 0.009 and r = 0.374, p < 0.0001) and albumin (r = 0.410, p < 0.0001 and 0.287, p < 0.0001), and inversely correlated with CRP (r = -0.223, p = 0.001 and r = -0.147, p = 0.027). The Kaplan-Meier analysis revealed survival advantages for both high-amylase and high-lipase groups in end-stage renal disease (ESRD) (CKD stage 5) patients (log rank, p < 0.001 and p = 0.02, respectively). In the Cox regression analysis, serum amylase was found to be an independent predictor for mortality. CONCLUSION: Serum amylase activity was found to be an independent predictor of mortality in ESRD patients. Relatively low serum pancreatic enzyme levels in CKD may be regarded as a novel component of the malnutrition-inflammation-atherosclerosis syndrome.
PURPOSE: Serum levels of amylase and lipase are frequently increased in patients with chronic kidney disease (CKD). Relatively low serum pancreatic enzyme levels in CKD may represent a state of pancreatic insufficiency and may contribute to protein-energy wasting (PEW). We aimed to investigate the relationships of serum pancreatic enzyme levels with PEW, inflammation, and mortality in CKDpatients. METHODS: Two hundred and thirty CKDpatients (male/female: 144/86; mean age, 59 ± 16 years) were enrolled. Serum total α-amylase and lipase activities were measured by enzymatic colorimetric assays. Mean follow-up time was 18 ± 10 months. Forty-seven patients (20 %) died during this period. RESULTS: Serum amylase levels were increased in 95 patients (41 %) and serum lipase levels were increased in 71 patients (30 %) out of the 230 patients. Diabeticpatients had significantly lower serum amylase levels than non-diabetic ones (86 ± 46 vs. 111 ± 60 IU/L, p < 0.0001). Patients with ischemic heart disease also had significantly lower serum amylase (82 ± 37 vs. 108 ± 60 IU/L, p < 0.0001) and lipase levels (39 ± 36 vs. 57 ± 57 IU/L, p = 0.007). Serum amylase and lipase levels were directly correlated with serum creatinine (r = 0.173, p = 0.009 and r = 0.374, p < 0.0001) and albumin (r = 0.410, p < 0.0001 and 0.287, p < 0.0001), and inversely correlated with CRP (r = -0.223, p = 0.001 and r = -0.147, p = 0.027). The Kaplan-Meier analysis revealed survival advantages for both high-amylase and high-lipase groups in end-stage renal disease (ESRD) (CKD stage 5) patients (log rank, p < 0.001 and p = 0.02, respectively). In the Cox regression analysis, serum amylase was found to be an independent predictor for mortality. CONCLUSION: Serum amylase activity was found to be an independent predictor of mortality in ESRDpatients. Relatively low serum pancreatic enzyme levels in CKD may be regarded as a novel component of the malnutrition-inflammation-atherosclerosis syndrome.
Authors: Marie Louise Malmstrøm; Mark Berner Hansen; Anders Møller Andersen; Annette Kjær Ersbøll; Ole Haagen Nielsen; Lars Nannestad Jørgensen; Srdan Novovic Journal: Pancreas Date: 2012-03 Impact factor: 3.327
Authors: Franciele D Vannini; Aline A Antunes; Jacqueline C T Caramori; Luis C Martin; Pasqual Barretti Journal: Int Urol Nephrol Date: 2009-12 Impact factor: 2.370
Authors: Akos Ujszaszi; Maria E Czira; Katalin Fornadi; Marta Novak; Istvan Mucsi; Miklos Z Molnar Journal: Int Urol Nephrol Date: 2012-01-14 Impact factor: 2.370
Authors: P Dandona; D B Freedman; Y Foo; J Perkins; A Katrak; D P Mikhailidis; S B Rosalki; A G Beckett Journal: J Clin Pathol Date: 1984-03 Impact factor: 3.411
Authors: D Fouque; K Kalantar-Zadeh; J Kopple; N Cano; P Chauveau; L Cuppari; H Franch; G Guarnieri; T A Ikizler; G Kaysen; B Lindholm; Z Massy; W Mitch; E Pineda; P Stenvinkel; A Treviño-Becerra; A Trevinho-Becerra; C Wanner Journal: Kidney Int Date: 2007-12-19 Impact factor: 10.612
Authors: Geng Zhang; Peijun He; Hanson Tan; Anuradha Budhu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Harris G Yfantis; Dong H Lee; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 12.531